A 48-year-old woman with newly diagnosed HER2-positive, hormone receptor-negative invasive ductal carcinoma of the breast is being evaluated for adjuvant therapy. What is the drug of choice for HER2-directed therapy in this patient?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.